Genedrive PLC Total Voting Rights (4022I)
05 8월 2023 - 12:00AM
UK Regulatory
TIDMGDR
RNS Number : 4022I
Genedrive PLC
04 August 2023
genedrive plc
("genedrive" or the "Company")
Application for Listing
Total Voting Rights
genedrive plc (AIM:GDR), the point of care molecular diagnostics
company, confirms that in order to support the further drawdown and
delivery of its GBP5M Equity Prepayment facility that was announced
on 31 March 2023, application has been made for the Admission to
trading on AIM of 3,050,000 new Ordinary Shares of 1.5p each ("New
Ordinary Shares"). Admission of the New Ordinary Shares
("Admission") is expected to occur on 10 August 2023. Following
Admission, the New Ordinary Shares will rank pari passu in all
respects with the Company's existing ordinary shares.
Following Admission the Company's issued share capital will
consist of 102,099,946 Ordinary Shares of 1.5p each and this figure
may be used by shareholders as the denominator for the calculations
by which they should determine if they are required to notify their
interest in, or change to their interest in, the Company under the
FCA's Disclosure Guidance and Transparency Rules.
For further details please contact:
genedrive plc +44 (0)161 989 0245
David Budd: CEO / Russ Shaw: CFO
Peel Hunt LLP (Nominated Adviser
and Joint Broker) +44 (0)20 7418 8900
James Steel / Patrick Birkholm
finnCap (Joint Broker) +44 (0)20 7220 0500
Geoff Nash
Walbrook PR Ltd (Media & Investor +44 (0)20 7933 8780 or genedrive@walbrookpr.com
Relations)
+44 (0)7980 541 893 / +44 (0)7876
Paul McManus / Anna Dunphy 741 001
About genedrive plc ( http://www.genedriveplc.com ) genedrive
plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and
robust point of need molecular diagnostics platform for the
diagnosis of infectious diseases and for use in patient
stratification (genotyping), pathogen detection and other
indications. The company are currently developing a genetic test
for CYP2C19 metaboliser status.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRNKQBDNBKDPFK
(END) Dow Jones Newswires
August 04, 2023 11:00 ET (15:00 GMT)
Genedrive (LSE:GDR)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Genedrive (LSE:GDR)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024